Voluntis Announces Changes to Its Governance
31 Luglio 2020 - 6:00PM
Business Wire
- Changes to the Board of Directors
- Evolution of the organization and leadership
appointment
Regulatory News:
Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN:
FR0004183960) announces today changes to its board of directors and
management structure, a new step in the implementation of its
strategic roadmap announced in March 2020.
Board of Directors
As Voluntis continues to simplify its organization in line with
its strategic roadmap, the Board of Directors has approved a
reduction in its size. In conjunction with this evolution, Roberta
Herman and Nicolas Cartier have resigned as members of the Board of
Directors due to each of them taking on new leadership roles: Dr
Herman as President and CEO of Joslin Diabetes Center and Mr.
Cartier as COO of Merieux NutriSciences. This revised Board
structure, with six directors of which two are independent, became
effective July 30, 2020.
“On behalf of my fellow directors, the company's management
team, and shareholders, I'd like to thank Roberta and Nicolas for
the significant contributions they made during their years of
service on the Voluntis Board," said Eric Elliott, Voluntis’
Chairman. “While we will miss the benefit of their contribution,
moving forward, a reduced size of our Board is consistent with our
decision to adopt a leaner company governance.”
Organization and leadership team
In parallel, the Company organization has been simplified to
sustain competitiveness and promote innovation and talents, whilst
assuring continuity in the Company’s skills, culture and
values.
The Executive Committee and the Global Management Committee are
now merged into a single Management Committee, led by the Chief
Executive Officer, Pierre Leurent. All commercial activities are
now regrouped under a single unit, headed by Romain Marmot,
appointed Chief Business Officer.
As a result of the organizational changes, the Chief Operations
Officer role has been removed and Alexandre Capet, former COO in
Europe, is leaving the company to pursue other interests.
About Voluntis Voluntis creates digital therapeutics that
empower people suffering from chronic conditions to self- manage
their treatment every day, thus improving real-world outcomes.
Combining mobile and web apps, Voluntis’ solutions deliver
personalized recommendations to the patient and the care team so
that they can, for example, adjust treatment dosage, manage side
effects or monitor symptoms. These real-time recommendations are
based on digitized clinical algorithms. Leveraging its Theraxium
technology platform, Voluntis has designed and operates multiple
digital therapeutics, especially in diabetes and oncology. Voluntis
has long-standing partnerships with leading life science companies.
Based out of Boston and Paris, France, Voluntis is a founding
member of the Digital Therapeutics Alliance. For more information,
please visit: www.voluntis.com
Mnemo : VTX - ISIN : FR0004183960
Disclaimer
This press release contains certain forward-looking statements
concerning Voluntis group and its business, including its prospects
and product candidate development. Such forward-looking statements
are based on assumptions that Voluntis considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
reference document of Voluntis registered with the French Financial
Markets Authority (Autorité des Marchés Financiers) under number
R.19-013 on April 26, 2019 (a copy of which is available on
www.voluntis.com) and to the development of economic conditions,
financial markets and the markets in which Voluntis operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Voluntis or not currently
considered material by Voluntis. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Voluntis to be materially different
from such forward-looking statements. Voluntis expressly declines
any obligation to update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200731005384/en/
NewCap Media relations Nicolas Merigeau
voluntis@newcap.eu +33 (0)1 44 71 94 98
NewCap Investor relations Louis-Victor Delouvrier
voluntis@newcap.eu +33 (0)1 44 71 94 94
Voluntis Chief Financial Officer Matthieu Plessis
investisseurs@voluntis.com +33 (0)1 41 38 39 20